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Abstract 
Background 
E-health tools are a new mechanism to expand patient care, allowing supplemental resources 
to usual care, including enhanced patient-provider communication. These applications to 
smoking cessation have yet to be tested in a hospitalized patient sample. This project aims to 
evaluate the effectiveness and cost-effectiveness of a tailored web-based and e-message 
smoking cessation program for current smokers that, upon hospital discharge, transitions the 
patient to continue a quit attempt when home (Decide2Quit). 
Design 
A randomized two-arm follow-up design will test the effectiveness of an evidence- and 
theoretically-based smoking cessation program designed for post-hospitalization. 
Methods 
A total of 1,488 patients aged 19 or older, who smoked cigarettes in the previous 30 days, are 
being recruited from 27 patient care areas of a large urban university hospital. Study-eligible 
hospitalized patients receiving usual tobacco cessation care are offered study referral. Trained 
hospital staff assist the 744 patients who are being randomized to the intervention arm with 
registration and orientation to the intervention website. This e-mail and web-based program 
offers tailored messages as well as education, self-assessment and planning aids, and social 
support to promote tobacco use cessation. Condition-blind study staff assess participants for 
tobacco use history and behaviors, tobacco use cost-related information, co-morbidities and 
psychosocial factors at 0, 3, 6, and 12 months. The primary outcome is self-reported 30-day 
tobacco abstinence at 6 months follow-up. Secondary outcomes include 7-day point 
prevalence quit rates at 3-, 6-, and 12-month follow-up, 30-day point prevalence quit rates at 
3 and 12 months, biologically confirmed tobacco abstinence at 6-month follow-up, and 
multiple point-prevalence quit rates based on self-reported tobacco abstinence rates at each 
follow-up time period. Healthcare utilization and quality of life are assessed at baseline, and 
6- and 12-month follow-up to measure program cost-effectiveness from the hospital, 
healthcare payer, patient, and societal perspectives. 
Discussion 
Given the impact of tobacco use on medical resources, establishing feasible, cost-effective 
methods for reducing tobacco use is imperative. Given the minimal hospital staff burden and 
the automated transition to a post-hospitalization tailored intervention, this program could be 
an easily disseminated approach. 
Trial registration 
Current Intervention Trial NCT01277250 
Keywords 
Tobacco, Smoking cessation, Hospitalized smokers, Study protocol, Internet intervention 
Background 
The health effects of smoking tobacco and their economic impact are well documented [1]. 
Alabama’s tobacco smoking prevalence rate of 22.5% [2] exceeds the national average of 
19.8% [3], with expected higher rates among hospitalized patients [4,5]. Tobacco cessation 
studies have demonstrated that proactive recruitment of patients for smoking cessation 
counseling engages a larger percentage of patients, and intensive counseling with at least 1-
month follow-up post-hospitalization is effective [6], with 3-month follow-up found even 
more effective [7]. However, even longer duration counseling in-hospital, without follow-up, 
was not found more effective [6]. Together, this suggests that, while hospitalization is an 
opportunity to introduce smoking cessation, post-discharge follow-up is essential. 
In Crossing the Quality Chasm, the Institute of Medicine emphasized that care should not 
occur just within face-to-face visits but that ‘access to care should be provided over the 
internet’ to foster continuous healing relationships [8]. Subsequent reports [9-11] and other 
groups [12], including the Centers for Medicare and Medicaid Services [13], have continued 
to support the concept of e-Health tools to increase patient access, motivate patients in their 
care, and re-engineer patient-centered care. Because of time constraints on providers, and 
with over 70 million Americans using the internet to access health-related information [14], 
computer- and internet-based tools are becoming widespread. Even in Alabama, with its low 
ranking on digital access, 61.7% of households have internet access with additional access 
through work or community resources [15]. Innovative supplemental e-resources are being 
created to augment brief tobacco-cessation counseling. These new web-based tools/programs 
present a unique opportunity to enhance continued smoking cessation for hospitalized 
patients after discharge. 
Secure patient-provider e-messaging systems have been found to improve patient satisfaction 
and increase practice efficiency while maintaining HIPAA standards [16,17]. The strategy of 
combining e-coaching and computer-automated tailored information has been shown to be 
successful [18]. Though these innovative web-based tools/programs present a unique 
opportunity, reports of web-based interventions for hospitalized smokers are limited [6] and 
no reviews or meta-analyses that included such programs had been found at the time of 
writing this manuscript [19,20]. 
In a meta-analysis, 17% of web- and computer-based smoking cessation out-patient 
interventions were found effective in doubling quit rates at 6 months among general 
population participants compared to controls [19]. Also, treatment effects for web-based 
smoking cessation interventions appear fairly stable over time, as a meta-analysis found 
cessation rates did not dissipate at subsequent follow-ups [21]. While many of the web-based 
smoking cessation programs are appropriate for any smoker, they may miss an opportunity to 
address specific relevance of smoking to the smoker’s recent hospitalization and the unique 
needs of the smoker in care-transition. For this reason, we have enhanced an existing web-
based smoking cessation program to address individualized post-hospitalization smoking-
cessation needs through e-messages. 
Methods/Design 
Study design 
This study uses a randomized controlled two-arm multiple follow-up design to: (1) test the 
effectiveness of the Decide2Quit intervention against usual smoking cessation care for 
hospitalized patients transitioning to outpatient care; and (2) determine the cost-effectiveness 
of each component of a smoking cessation intervention for hospitalized smokers (the 
Decide2Quit post-hospital intervention and usual care). The primary outcome for 
effectiveness is self-reported 30-day point prevalence at 6 months post-hospitalization. 
Secondary outcomes are: biologically confirmed smoking cessation at 6 months; 30-day point 
prevalence at 3 and 12 months; and 7-day point prevalence at 3, 6, and 12 months. 
Consecutive abstinence will be assessed using the three 30-day point prevalence data. The 
cost-effectiveness of the intervention compared to usual care will be determined by 
considering costs of intervention implementation and costs of healthcare with effectiveness 
measured in terms of Quality Adjusted Life Years (QALYs). 
This study has obtained approval from The University of Alabama at Birmingham (UAB) 
Institutional Review Board for Human Use (IRB). All study personnel are IRB trained and 
Health Insurance Portability and Accountability Act (HIPAA) certified. 
Setting and sample 
The setting for this study is UAB Hospital, a 1,000 bed state-of-the-art academic center 
hospital with 43 patient care areas (PCAs). Of these, 27 PCAs serve patients potentially 
eligible for study participation. The 16 PCAs not included in this study, maternity and 
palliative care units and some intensive care and psychiatric units (acute, dementia, and 
adolescent care), are excluded due to the difficulty of obtaining informed consent and/or the 
unique smoking cessation needs among the patients served. As well, we will over-recruit 
smokers with pulmonary and cardiac diseases, as this population is of primary interest to the 
study collaborative. While UAB Hospital has a non-smoking policy, and patients are 
expected to abstain from tobacco use while hospitalized, non-adherence to this policy has 
been noted in patients sufficiently mobile to go outdoors. 
The UAB Lung Health Center staff receive a daily report of all current smokers admitted to 
UAB Hospital during the previous 24 h to provide or facilitate the provision of tobacco 
cessation usual care at bedside (see Table 1 for description of this component). After 
provision of usual bedside care, all potentially eligible patients admitted to the selected PCAs 
between July 2011 and May 2013 will be given the opportunity to learn about the study and 
enroll. To be eligible for the study, patients must meet the following criteria: (1) over the age 
of 18; (2) a current smoker defined as at least one puff in the past 30 days; (3) read and speak 
English; (4) able to provide meaningful responses to the screening questions and to provide 
informed consent; (5) have an email address and internet access through self or surrogate; 
and, (6) not have another household member participating in the study.  In addition, patients 
under isolation precautions, except for contact isolation only, are not approached for 
participation. Criteria 2, 4 and 6 are common to all CHART sites. 
Table 1 Intervention and usual care contacts by type, timing, and instigator 
 Type of contact Timing Instigator 
Usual Care + Usual Care Admission booklet page 
on smoking 
At admission Hospital admitting staff 
Smoking Cessation local 
resources handout and 
brief counseling 
During hospital stay Lung Health Center staff 
Smoking cessation 
information in discharge 
packet
a
 
At discharge Hospital assigned nurse 
 Intervention Website registration and 
orientation 
Prior to discharge Hospital Quit Staff 
Tailored e-mails Weekly for 12+ 
weeks
b
 
Automated by web system 
Telephone call 7 to 14 days post-
discharge 
Hospital Quit Staff 
Secure messaging At will Participant or Quit Advisor 
(Tobacco Treatment 
Specialist) 
Website use At will Participant 
a
A portion of which is provided optionally at the discretion of the hospital-assigned nurse. 
b
Minimum of 12 weeks, longer if participant changes their readiness to quit status. 
Participant recruitment and randomization to condition 
Study staff verify eligibility with a screening assessment that includes questions about 
internet access and use of e-mail, the participation of other household members in this study, 
and mental status (if in question). Eligible patients are provided an overview of the study and 
a chance to ask questions prior to providing written informed consent. After completion of 
baseline assessments and listing on the electronic study roll by study staff, patients are 
randomized to study condition (intervention or usual care). Blocked randomization within 
each PCA is used to reduce selection and accidental bias and achieve balance in the 
allocation of participants to treatment arms. The study statistician generated random number 
lists for each PCA prior to study initiation. The Study Coordinator identifies the participants 
to randomize to study condition each day based on their order of listing on the study roll and 
the allocation indicated for the PCA in which they were recruited. As participants are 
allocated to the intervention arm, the Study Coordinator sends e-mail alerts to designated 
hospital staff (Quit Staff) that newly randomized patients need to be registered to the 
intervention website, Decide2Quit. Figure 1 depicts the recruitment and initial study activities 
flow. 
Figure 1 Participant eligibility and recruitment flow 
Intervention description 
The intervention includes tailored e-mail messages and an interactive website (Decide2Quit) 
designed for post-hospitalization smoking cessation which allows secure messaging with a 
certified Tobacco Treatment Specialist (TTS) (Quit Advisor) and both in- and post-hospital 
contact by the hospital Quit Staff. The Quit Staff visit patients assigned to the intervention 
arm at bedside to assist them with registration to Decide2Quit using secure laptops connected 
to the website via the hospital’s Wi-Fi system. The Quit Staff then orient the participants to 
the website by displaying general content areas and available quit tools. Participants also 
receive a booklet illustrating how to access and navigate the website. In addition, this booklet 
features study contact information for technical problems, blank copies of the website ‘quit 
plan’, and a letter for their primary healthcare provider. This letter contains study-related 
information and requests the healthcare provider’s verbal and pharmaceutical (as appropriate) 
support of their patient’s quit attempt. 
Some patients randomized to the intervention are discharged from the hospital before the 
Quit Staff can visit them to provide website registration and orientation. The print materials 
are mailed to these participants and Quit Staff provide telephone assistance with website 
registration and orientation. The Quit Staff make one follow-up telephone contact, at 7 to 14 
days post-discharge, to encourage website use in the context of the primary area of health 
concern the participant identified at website registration. 
Theoretical framework and intervention e-messages 
Two behavioral change theories are the basis for both the website content and e-mail 
messages: Social Cognitive Theory [22] and the Transtheoretical Model [23]. Two types of 
email messages are sent: tailored to stage of change and tailored to health concern. Stage of 
change messages are framed to address where each participant has self-identified along the 
quit continuum, from no interest in quitting to already quit. For example: those with no 
interest in quitting receive messages containing information about benefits to quitting and 
harm reduction; those actively trying to quit receive messages that promote self-efficacy to 
avoid smoking situations and overcome cravings; and, those already quit receive messages 
targeting relapse prevention. Participants confirm or change their smoking stage status at 
each website login. While a set number of messages are available for each stage, when the 
participant changes their stage, messages ‘start over’ with the messages for the new stage, 
thereby increasing the total number of messages sent. 
The health concern messages, sent weekly for 12 weeks, are based on the primary area of 
health concern identified by the participant at website registration (cancer, lung disease, heart 
disease or stroke, surgery or wound healing, or none of these). E-mail messages provide 
general information related to the selected health concern, without specifying protected health 
information. Outcome expectations and other theoretical constructs provide the basis for the 
messages. For example, someone selecting ‘surgery or wound healing’ would receive the 
message ‘Quitting smoking allows more blood with oxygen to reach wounds to help them 
heal faster’ while someone selecting ‘heart disease or stroke’ would receive ‘In just one day 
of quitting, you will have started to lower your risk of having a heart attack. Every day you 
stay quit, you lower your risk of having a heart attack more.’ Those choosing ‘none of these’ 
receive general health messages. Each message ends with promoting website use by 
providing the link to ‘learn more about…’. Table 1 summarizes the intervention contacts. 
Website content 
This intervention website is a modification and refinement of an existing version of 
Decide2Quit which is the product of two Investigators’ prior NIH-funded research efforts to 
develop web-delivered smoking cessation systems for patients [24] and providers [25]. The 
website continues to include an interactive quit-support calculator (questionnaire with 
feedback focusing on decisional balance, triggers, risks, and smoking-related symptoms), 
models for communication with health providers and family members, educational materials, 
a secure messaging system to access a TTS (Quit Advisor), and access to a social network of 
online smokers (BecomeAnEx). The current site has been expanded and tailored to better 
serve the unique needs of recently hospitalized adult smokers by providing information on 
how quitting reduces specific health risks, and the temporary physical and emotional side 
effects of quitting. The administrative side of the website includes the ability to track patient 
web activity and smoking status, document follow-up phone calls by the Quit Staff, and 
monitor participant-generated messages to the Quit Advisor (using the compose function on a 
secure, HIPAA-compliant messaging system using Secure Socket Layer technology and 
hosted on a separate server used exclusively for Decide2Quit). Thus, the intervention has 
both patient-facing and administrative components. 
Identifying and training hospital staff 
Meetings with various hospital staff groups led to the identification of respiratory therapists 
as the most appropriate hospital staff (Quit Staff) for this study given their professional role 
in lung health and their hospital-wide duties. When the respiratory therapists’ duties preclude 
assisting with patient registrations, a hospital-paid smoking cessation staff provides this 
service. Quit Staff provided input into the development of the administrative portal they use 
to track contact with intervention participants, as well as practical suggestions for how best to 
implement this intervention in UAB Hospital. Quit Staff training includes a didactic overview 
of the study, information on specific protocols (registration, orientation, and follow-up 
telephone contact) and the website, and a hands-on computer training for the website, from 
both the patient and administrative perspectives. 
Data collection and measurements 
Survey data collection takes place at the hospital bedside for baseline and via telephone 
interview for the 3- , 6-, and 12-month follow-up. Additional biologic measures are collected 
at 6-month follow-up as described below. Tables 2 and 3 describe the measures to be 
collected at each time point. Measures are noted as Tier 1 (core across all collaborative 
projects), Tier 2 (optional measures, standard across projects), or Tier 3 (specific to this 
project). Study staff who conduct assessments are blinded to participant condition and are 
trained to collect all data uniformly according to written protocols. Data are entered directly 
into an internet-based survey system using security-enabled laptop computers with either Wi-
Fi (at bedside) or hard-wired internet access. All questions require responses by the system to 
facilitate complete datasets (‘refused’ and ‘does not know’ response options available). Study 
staff are trained to complete paper copies should there be difficulty in accessing the internet, 
with the study data manager later entering the data into the database. Some data are acquired 
from patients’ electronic medical records, study records, or outside sources, as noted in Table 
3. 
Table 2 General assessments and time-points 
Tier
a
 Measure Details Month 
0
b
 3 6 12 
1 Demographics
c
 Age, length of stay, insurance, height, 
weight, ICD-9 codes, DRGs, Procedure 
codes, admission type, discharge ‘to’ 
plan, race, ethnicity, gender, education, 
marital status, other household smokers 
X    
1 Smoking status Self-reported - last 7 days  X X X 
1 Smoking status Self-reported - last 30 days X X X X 
3 Smoking status Prolonged abstinence (multiple point 
prevalence) 
 X X X 
1 Quit plan Post-hospital plans regarding quitting X    
1 Other tobacco use Other than cigarettes - last 30 days X X X X 
2 Tobacco dependence Heavy Smoking Index (2 questions) X X X  
2 Tobacco cessation treatments Behavioral and pharmacologic treatments, 
dose/frequency, length of use 
X  X X 
3 Pack-history Lifetime X    
3 Longest abstinent period Lifetime at 0 months; past year at 12 
months 
X    
1/3 Satisfaction Satisfaction with smoking cessation help  X   
3 Quit attempts Past year (over 24 h abstinent) X  X  
3 Social support Perceived support from significant others 
to quit/abstain 
X    
3 Internet and e-mail use Frequency and type of use X    
1 Self-efficacy for abstinence Single question X  X X 
3 Self-efficacy for abstinence SEQ12 X  X  
2 Alcohol use Audit-C X  X  
2 Depressive symptomology PHQ-2 X  X  
2 Saliva cotinine, exhaled CO, 
surrogate corroboration
d
 
Validate 7-day smoking status   X  
a
Tier 1 = common to all CHART trials, Tier 2 = common among some CHART sites, Tier 3 = 
this site only. 
b
Month 0 = Baseline. 
c
Some data collected after hospital discharge from electronic medical records and discharge 
summaries. 
d
Randomly selected sample of past-7-days smokers and all past-7-days non-smokers. 
Table 3 Data collection for cost effectiveness analysis 
Cost
a
 Tier Data item Description Valuation 
Cost of usual 
care 
1 LHC staff time LHC staff time spent at bedside Average time 
per patient 
1 Hospital nurse 
time 
Time spent by assigned nurse assembling 
discharge packet (containing usual care) 
Average time 
per patient 
1 Materials Cost of printing Actual costs 
Cost of 
intervention 
1 Hospital Quit Staff 
training 
Time of trainers and trainees, materials, and 
so on 
Study records 
1 Hospital Quit Staff 
time 
Time spent on each patient in preparation, 
implementation, and documentation of 
website registration/orientation and 7-14 days 
post-discharge follow-up call 
Average time 
per patient 
Web tracking 
1 Quit Advisor time Time spent on each patient in preparation, 
implementation, and documentation of 
responses to patient-generated messages 
Average time 
per message 
1 Patient materials Brochures, booklets, and so on Study records 
1 Website 
implementation 
(not development) 
(To be determined, though may contain 
maintenance, servers, programming, content 
updating, emailing, and so on) 
Study records 
1 Time of participant 
on website 
Time recorded on website per personal login; 
number, frequency, and content of messaging 
to Quit Advisor through the Decide2Quit 
website 
Website 
tracking 
 Month/Source 
0 3 6 12 
Healthcare-
related costs 
2 Healthcare 
utilization 
Hospitalizations, outpatient visits, procedures, 
Emergency Room visits (last 6 months) 
(No/Yes - # times) 
X  X X 
2 Time/cost related 
to care 
Time (hours) off work for participant and 
others who accompany participant to visits 
X  X X 
Gender-age group average wages for the state Bureau of Labor 
Statistics 
2 Out-of-pocket 
(OOP) costs 
Co-payments, deductibles, transportation, 
parking, meals, and so on (including 
caregivers, when applicable) (last 6 months) 
  X X 
2 Costs to healthcare 
payers 
Reimbursements to healthcare payers 
according to type of care 
Hospital bills / 
Medicare 
reimbursements 
2 Medicines Co-payments, deductibles, OOP costs (last 6 
months) 
X  X X 
Wholesale price for healthcare payers Red Book 
Smoking 
cessation 
products / 
programs costs 
3 OOP costs Co-payments, and so on. (last 6 months) X  X X 
2 Reimbursements Reimbursements for healthcare payers TBD 
Quality of life 2 EQ-5D-5L [26]  X  X X 
 3 SF-12  X  X X 
a
All costs will be expressed in the same year of currency. 
Biologic measures 
At 6-month follow-up, participants are contacted by telephone and asked about their past-7-
days’ smoking status. Participants reporting not smoking in the past 7 days and living within 
a 40-min commute are asked to come to the clinic for in-person saliva collection, for cotinine 
testing, as well as a Carbon Monoxide (CO) measure. Those living farther away are mailed 
saliva collection kits as described in the CHART biochemical verification study (see Riley et 
al. CHART Overview paper). A random sample of self-reported past-7-day tobacco users are 
asked to provide saliva samples in the same manner as non-smokers. For past-7-days 
smokers, study staff check a random selection list to determine if the participant is selected to 
provide a biologic specimen. We anticipate this sample to be about 10% of the past-7-days 
smokers. At the time of the telephone interview, those participants who are to provide in-
person biologic measures are scheduled to come into the clinic within the following 2 weeks. 
If a participant misses two scheduled clinic appointments, a saliva kit is mailed with follow-
up attempts the same as for all mailed kits. 
The primary biologic measure is saliva cotinine measurement. Salivary cotinine is considered 
a very sensitive measure for determining smoking status [27,28]; a level of <15 ng/mL 
confirms abstinence [29,30]. Exhaled air CO levels in exhaled air are measured with a 
Bedfont Smokerlyzer; a level of <10 parts per million confirms abstinence [31]. CO is 
considered the primary biological confirmation measure when the saliva cotinine measure is 
considered potentially invalid due to current use of nicotine replacement therapy or alternate 
tobacco products. If a selected participant is unable to attend the 6-month in-person visit, 
every attempt is made to collect the specimen by mailed saliva sample kit or home visit (or 
other mutually agreed upon meeting place) by study staff. When no biological measure can 
be acquired from a participant, study staff attempt corroboration of self-reported smoking 
status from another person (contact information and permission to contact provided by 
participant at previous contact). 
Participant incentives 
Participants are provided checks as incentives for completion of the follow-up data collection 
portion of this project to compensate for their time and effort. For survey completion: a $20 
check is mailed after the 3-month telephone follow-up and $25 checks are mailed after each 
of the 6- and 12-month follow-ups. Those providing saliva samples in the clinic receive a 
$100 check at the end of visit, while those providing mailed samples will be sent a $75 check 
upon receipt of the mailed saliva sample. 
Process measures 
To ensure that the study protocol is implemented with fidelity, systems- and records-based 
data are collected on an ongoing basis. Process measures fall into three areas: (1) recruitment 
and retention; (2) intervention delivery and dose; and (3) staff productivity. Study 
investigators review reports monthly to monitor study activities and make recommendations 
for remediation as needed. Reports include the proportion of patients participating (or lost) at 
each level of screening and study activity (Figures 1 and 2). Intervention delivery and dose 
data collected include website log-ins, tailored e-messages sent, secure messages generated, 
and post-hospitalization telephone call receipt. Quit Staff manually enter the telephone call 
information into the website’s administrative portal while all other data are collected 
automatically by the website system. Staff productivity is monitored to ensure both protocol 
fidelity and timely completion of the study. These data include contact rates by the Quit Staff 
(bedside/telephone registrations and follow-up phone calls) and individual recruitment and 
retention rates for each study staff. Ongoing performance feedback from the Study 
Coordinator is provided to staff with appropriate recommendations. 
Figure 2 Study flow diagram from enrollment to analyses 
Sample size estimate 
We have estimated the total number of participants recruited during the 22-month recruitment 
phase of this study as 1,488 based on published and UAB-specific information. Given 
published findings that smoking rates among hospitalized patients exceed general population 
rates [4,5,32-35], the estimated current rate of smoking in Alabama (22.5%) [2], and the 
UAB Hospital 2009 data (24% to 32%, depending on the ICD-9 codes used to define current 
smokers), we estimate that at least 24% of UAB Hospital inpatients will be current smokers. 
Among hospitalized smokers in other studies, 60% to 82% desired to quit and expressed 
willingness for post-hospitalization smoking cessation contact [4,33,36]. Almost 62% of 
Alabama households have internet access [15]; we anticipate 50% of our hospitalized patients 
who smoke will have internet access, given the likelihood of being from a lower 
socioeconomic status. Based on current admission trends, we expect an average of 10 new 
patients to meet eligibility criteria on a typical day within the 27 PCAs targeted, with at least 
half willing to receive information about the study. It is anticipated that the study 
population’s demographics and reasons for hospitalization will mimic the general population 
of hospitalized smokers at UAB Hospital (based on 2009 hospital data): 60% male, 43% 
African American, 1.5% Hispanic, 1.3% Asian, and <1% of other racial/ethnic background, 
with approximately 17% having acute myocardial infarction (AMI), pneumonia, and/or 
congestive heart failure (CHF). 
Power estimate 
Power is estimated for the primary outcome: differences in self-reported smoking abstinence 
rates between the two treatment conditions at 6 months post-hospitalization based on 30-day 
point prevalence. Rates for smoking cessation reported in the literature for ‘usual’ post-
hospitalization care are 5% to 15% at 6 months and 7% to 10% at 1 year [37]. With 1,488 
participants, 744 assigned to each treatment condition, using 12% as an estimated rate for the 
comparison group, this study will be powered (β = 80%-type II error, α = 0.05-type I error) to 
detect a difference of 5.12% between the two treatment conditions (two-sided). For the 
intervention condition, a sub-analysis between the group with one of three diagnoses (CHF, 
AMI, or pneumonia - expected n = 256) and the group with all other diagnoses (expected n = 
488) will have sufficient power (β = 80%-type II error, α = 0.05-type I error) to detect a 
difference in tobacco abstinence rates of 9.4% (two-sided), assuming the three-diagnoses 
comparison group has a 25% quit rate (two-sided). Note that, as the smoking cessation rate 
increases for the comparison group, a larger difference is necessary between groups to 
achieve a specific level of power, which is why a higher rate is used for power computation. 
The reverse of this is true as well: as the comparison group rate decreases, a smaller 
difference between groups achieves the same level of power. 
Data analyses 
Primary and secondary outcomes analyses 
The study analyses will be conducted using the most up-to-date version of SAS (SAS 
Institute, Cary, NC, USA) and P ≤ 0.05 will be considered significant for all analyses, except 
where Bonferroni correction for multiple comparisons is necessary. Baseline characteristics 
of both groups will be compared to ensure that random assignment results in comparable 
groups. Any factors not found balanced across randomization groups will be adjusted for in 
subsequent models. Continuous variables will be compared using a two-sample t-test, while a 
chi-square test of association will be used to compare categorical variables. 
The primary outcome for this study will be self-reported 30-day tobacco abstinence rates at 6-
month follow-up. For missing outcome data at the 6- and 12-month follow-ups, we will 
impute missing data using a propensity-based multiple imputation method [38] that has been 
agreed upon for the collaborative [39]. This approach assumes that non-response is random 
which is more robust than assuming all non-responders are smokers [40]. Using baseline and 
any additional available data (for example, 3-month survey), we will use a logistic regression 
model to estimate the propensity to respond to the follow-up survey for each hospital stratum 
and treatment arm combination. Within each combination we will stratify further based on 
values of the estimated propensities and then impute a value for the outcome for each non-
respondent by randomly sampling from the respondent values within their sub-stratum. 
Multiple datasets will be created and the point estimates and the estimated standard error 
from each dataset will be combined to arrive at a single point estimate, its estimated standard 
error, and the associated confidence interval or significance test [40]. Given the potential for 
missing data not-at-random, we will further implement a pattern-mixture analyses [41] based 
on content experts and the observed patterns of missing data. 
We will also run a responders-only analysis for descriptive purposes. A two-sample test for 
the difference in proportions will be used to test whether the quit rates are different between 
the two treatment conditions (two-sided) and, if indicated, whether the Decide2Quit 
intervention is effective in promoting smoking cessation compared to the usual care group 
(one-sided). We will conduct this same statistical analysis for secondary outcomes. 
Several covariates may affect the relationship between the intervention effect and the quit 
rate. Potential covariates include age, tobacco dependence, major health issue, number of 
diagnostic codes assigned at hospital discharge, race, smoking history, alcohol use, 
depressive symptoms, social support, use of other smoking cessation programs, and self-
efficacy. Because participants are randomized to treatment arm, these potential covariates 
will theoretically be balanced across the two arms. However, the strength of the association 
between each of these covariates and the quit rate will be assessed in a logistic regression 
model. This analysis will provide the variables that are predictive of smoking cessation 
among all smokers and can be repeated to test for predictors among the three diagnostic 
groups (AMI, pneumonia, and CHF) vs. all other diagnostic groups. Secondary exploratory 
analyses are planned to investigate a range of broader issues related to smoking cessation. An 
analysis similar to the primary analysis will test potential differential effects of the 
Decide2Quit intervention among diagnostic groups by comparing those patients with AMI, 
CHF, and/or pneumonia to patients not having these diagnoses. A third set of tests of 
proportions will compare each of the three diagnostic groups of interest in the intervention 
condition to their matching group in the usual care condition (although power will be limited 
due to small sample sizes). The relationship between dose and smoking cessation will be 
examined using logistic regression tests, as we expect dose will not be normally distributed. 
Cost-effectiveness analyses 
The cost-effectiveness will be conducted from the perspectives of the hospital, healthcare 
payers, patients, and society. Analyses will be conducted for the short-term of the trial and for 
the lifetime of participants using modeling techniques and data from the literature, using the 
established cost-effectiveness analyses measures common to participating CHART projects. 
Effectiveness will be measured using Quality Adjusted Life Years (QALYs) which will be 
calculated using the EQ-5D-5L [26]. See Table 2 for all measures related to cost-
effectiveness. Incremental cost-effectiveness ratios (ICERs) will be calculated by dividing the 
net cost of Decide2Quit by its effectiveness, that is, QALYs saved by the intervention. ICERs 
will be calculated if Decide2Quit is effective in improving QALYs and is more expensive 
than usual care. Ratios will be compared to others published in the literature to determine if 
the Decide2Quit intervention is cost-effective. ICERs do not need to be calculated if 
Decide2Quit is cost-saving, that is, more effective and not more costly than usual care. To 
examine the robustness of, and the impact of parameter uncertainty on these results, 
univariate and multivariate sensitivity analyses [42] will be used. 
In addition, a non-parametric bootstrap method [43-46] will be used to sample with 
replacement costs and outcomes from usual care and intervention arms. In cost-effectiveness 
analyses, non-parametric bootstrapping is one of the methods used to allow the comparison of 
arithmetic means of cost data, which usually are heavily skewed to the right. In the case the 
cost data are distributed normally, we will use parametric statistical testing. The 
bootstrapping also is used to examine uncertainty in cost-effectiveness analyses. Relying on a 
conventional confidence interval of the cost-effectiveness ratio is complicated by the fact that 
a positive ratio indicates a case of the intervention being more effective and more costly than 
the comparison (and thus may be cost-effective) and indicates a case of an intervention being 
less effective and less costly than the comparison. A depiction of cost and effect differences 
of the bootstrap samples on a cost-effectiveness plane will allow us to better consider these 
cases and understand the variability around the ratio. The difference in costs and outcomes of 
each bootstrap sample, obtained by repeating the procedure 1,000 times, will be plotted in a 
cost-effectiveness plane. An acceptability curve then will be obtained by considering the 
proportion of bootstrap replications for which the CE ratio falls below each possible value of 
cost per QALY, including the commonly used $100,000/QALY. This information will allow 
a better understanding of the probability of the Decide2Quit intervention being cost-effective. 
Discussion 
There is considerable research on smoking cessation among outpatients and among inpatients 
with respiratory or cardiac disease. However, for general inpatient smokers, there is little 
information on programs that transition to post-hospitalization and most have follow-up 
limited to less than 6 months. Rates of smoking cessation immediately post-hospitalization 
are high, but relapse rates are also high [47]. Conceptually, relapse prevention should begin 
in the hospital and continue after discharge, as the crucial time for relapse occurs 1 week after 
quitting [48]. For many patients, this is concurrent with discharge and the return to a 
smoking-related routine with deeply engrained smoking-related behaviors [6]. Despite this 
knowledge, cessation interventions designed to transition patients from hospital to home have 
not widely diffused into usual clinical practice. This study will add to the limited literature 
about smoking cessation in the general inpatient population as well as smoking status at 12 
months post-hospitalization. 
Identifying appropriate hospital staff to register patients for a smoking cessation program was 
a challenge in the current healthcare system. A strong interest in tobacco cessation and access 
to and familiarity with all areas of the hospital are considered essential. As hospital resources, 
environments, and staffing vary, different hospital personnel may be identified as most 
appropriate. After discussions with personnel on many levels and areas of this hospital, 
respiratory therapists were identified as the best fit. Regardless, having committed champions 
among the hospital staff, or even better dedicated hospital staff, is imperative for successful 
implementation and the institutionalization that leads to program sustainability. 
Given the unknown validity of self-reported health behaviors and the expense and difficulty 
of collecting biological specimens, this study also aims to determine the validity of self-
reported smoking status for both self-reported quitters and non-quitters post-hospitalization. 
Participants are not informed of their selection for biological confirmation until after their 
quit status is assessed via telephone. We anticipate these findings will provide an algorithm 
for estimating true rates of smoking status from self-reported rates in future studies, 
increasing confidence in findings while reducing costs and allowing more precise measures 
of cost-effectiveness. 
A limitation of this study is that the intervention is designed for the general medical or 
surgical patient. We are not involving adolescents, acute psychiatric patients, and maternity 
patients as these individuals have unique needs. Ideally, we would include all smokers 
hospitalized within our medical hospital complex, to be able to meet the needs of every 
patient in the hospital population; however, given resource and time constraints, it is not 
feasible for this study. In the future, this website intervention could be expanded, similar to 
how this study’s website is an expansion of one originally developed for outpatients, to 
include messages and web pages tailored to meet the needs of these groups. As well, it could 
be tailored to specialty hospital populations. Another limitation of this study is potential 
selection bias given that a large proportion of our potential participant pool does not have 
internet access, a requirement for study participation. Those on the other side of the ‘digital 
divide’ may vary from our study sample in terms of smoking habits, concomitant tobacco 
use, or other salient attributes. This limits the generalizability of the findings to this study to 
the proportion of the hospitalized population with internet and e-mail capability. 
We have developed a tailored web-based program in an effort to apply these new e-health 
tools to facilitate the transition of the hospitalized smoker to the outpatient arena. This study 
will examine the effectiveness and cost-effectiveness of this smoking cessation program that 
is facilitated by hospital staff and links the discharged patient to a certified TTS and the 
intervention program for as long as needed. If this program proves to be effective and cost-
effective, it will be an approach that could easily be adopted by other hospitals. 
Trial status 
This study began recruitment July 17, 2011 and will continue to enroll participants until May 
2013. 
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